Key Highlights
- Regeneron’s melanoma treatment candidate fianlimab did not achieve its primary objective in a late-stage clinical study when compared to Merck’s blockbuster Keytruda.
- The drug combination of fianlimab plus Libtayo failed to demonstrate statistically meaningful gains in halting disease advancement.
- Shares of REGN plunged 11% to $618 during premarket hours on the announcement.
- Several major Wall Street firms reduced their price forecasts; Citi slashed its rating from Buy to Neutral and lowered its target from $900 to $700.
- RBC Capital reduced its outlook to $707, highlighting the setback as another addition to recent development program disappointments.
Shares of Regeneron Pharmaceuticals experienced a significant decline during Monday’s premarket session after the biotech company disclosed that its investigational melanoma therapy fianlimab failed to achieve its primary clinical objective in a pivotal late-stage study.
Regeneron Pharmaceuticals, Inc., REGN
The biotechnology firm’s shares tumbled 11% to $618 before the opening bell. The sell-off followed a Friday evening disclosure regarding the Phase 3 clinical trial outcomes.
The study evaluated fianlimab, an immune-based cancer therapy designed for advanced melanoma patients, administered alongside Regeneron’s existing drug Libtayo. This combination regimen was compared head-to-head against Merck’s powerhouse immunotherapy Keytruda, which ranks among the world’s top-selling oncology medications.
Researchers enrolled 1,546 melanoma patients divided into four treatment arms ā a high-dose combination therapy, a low-dose combination approach, Keytruda paired with placebo, and Libtayo combined with placebo.
The investigational treatment failed to demonstrate statistically meaningful enhancement in progression-free survival metrics. Simply put, the therapy did not effectively slow cancer advancement or reduce mortality when measured against Keytruda’s performance.
While a higher-dose formulation of the fianlimab-Libtayo combination demonstrated numerical advantages over Keytruda, these findings fell short of achieving the statistical significance threshold required to be clinically meaningful.
The disappointing trial outcome triggered a cascade of negative analyst reactions and revised price projections across Wall Street.
Analyst Community Responds
Geoff Meacham from Citi Research downgraded Regeneron from Buy to Neutral while dramatically reducing his price objective to $700 from $900. He emphasized that removing fianlimab from financial projections eliminates “incremental positive catalysts” that would support a premium stock valuation.
Jefferies analyst Akash Tewari characterized the trial failure as “not particularly” unexpected, describing it as confirmation of the pessimistic investment thesis. Despite maintaining his Buy recommendation, he reduced his price forecast to $870 from $890 and eliminated fianlimab from his revenue models.
RBC Capital Markets adjusted its target downward to $707 from $762 while maintaining its Sector Perform stance. The investment firm had previously projected peak risk-adjusted revenue between $1.6 billion and $1.8 billion for fianlimab in melanoma treatment ā projections now completely eliminated.
Development Pipeline Challenges Accumulate
RBC Capital characterized the fianlimab disappointment as emblematic of a troubling trend. The firm referenced additional recent difficulties including unsuccessful itepekimab trial outcomes, a less favorable regulatory label for Eylea HD, and production complications.
Regeneron’s flagship Eylea franchise experienced a 10% revenue contraction during the first quarter, which had previously pressured share performance earlier this year. Truist Securities reduced its price target to $769 due to regulatory timeline delays, while maintaining its Buy recommendation based on better-than-anticipated Q1 financial performance.
The analyst community hasn’t uniformly turned negative. BofA Securities maintained its Buy designation with an $860 price objective despite the clinical setback. Jefferies similarly retained its positive outlook.
On a more optimistic note, Dupixent ā jointly developed with partner Sanofi ā maintains robust growth momentum, expanding into additional medical indications and surpassing revenue forecasts. Eylea HD is reportedly recovering its trajectory, and Regeneron’s balance sheet shows a cash position exceeding total debt obligations.
According to InvestingPro analytics, thirteen analysts have adjusted their earnings projections downward for the upcoming reporting period.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
